Univercell Biosolutions
About Univercell Biosolutions
Univercell-Biosolutions has coupled the potential of human hiPS and hES cells with cellular reprogramming and directed differentiation technologies. Together these innovations yield purified populations of specific human cell types for drug-discovery applications. Univercell-Biosolutions has developed MesopureĀ® to provide a pure (>99%) population of cardiovascular progenitors. Univercell-Biosolutions works with clinicians, academics and industry leaders to develop next-generation homogeneous, mature, functional and differentiated human cells with physiological characteristics closely matching those of adult differentiated cells in vivo. Univercell-Biosolutionsā goals are to accelerate the discovery of new therapeutics and to reduce the drug failure rate in clinical trials.
Company Metrics
- Employees: 11-50
- Monthly Visits: None
- Tech Stack: 17 active products
Financial Information
- Estimated Revenue: Less than $1M
- Total Funding: 50000 EUR
- Last Funding: 50000 EUR (Grant)
- Funding Status:
Technology Stack
Univercell Biosolutions actively uses 17 products in their tech stack.
Market Presence
Industries: Biotechnology, Health Care, Wellness
Headquarters: Toulouse, Midi-Pyrenees, France